Letrovena

Letrozole, the active ingredient in Letrovena, is a aromatase inhibitor presented as a unknown/unknown for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrovena as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrovena, an aromatase inhibitor, is employed in the management of estrogen‑dependent breast cancer. - Hormone receptor‑positive breast cancer (adjuvant): Reduces risk of recurrence after surgery. - Hormone receptor‑positive breast cancer (metastatic): Helps control disease progression. - Estrogen‑dependent breast cancer (postmenopausal): Lowers estrogen levels to inhibit tumor growth.

Letrovena may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Arthralgia: joint pain or stiffness. - Headache: pressure or throbbing sensation. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Bone fracture: increased risk due to reduced estrogen. - Deep vein thrombosis or pulmonary embolism: blood clot formation. - Severe liver dysfunction: elevated enzymes or hepatitis. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - QT interval prolongation: potential cardiac rhythm disturbance. - Severe osteoporosis: marked loss of bone density.

Before initiating Letrovena, several safety considerations should be reviewed. - Monitor bone health: assess bone mineral density periodically. - Evaluate liver function: conduct baseline and periodic liver enzyme tests. - Assess cardiovascular risk: watch for signs of thrombosis. - Review concomitant medications: avoid known major interactions. - Counsel on menopausal symptoms: discuss management of hot flashes and sweating. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Letrovena can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Tamoxifen: concurrent use may reduce therapeutic effect of letrozole. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower letrozole plasma concentrations. - Anticoagulants (e.g., warfarin): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine, paroxetine): may raise letrozole levels. - Diabetes medications (e.g., metformin, insulin): monitor glucose control as hormonal changes can affect metabolism.